Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TECARTUS safely and effectively. See full prescribing information for TECARTUS. TECARTUS® (brexucabtagene autoleucel) suspension for intravenous infusion Initial U.S. Approval: 2020
Medication labelWhy this: Advisory · dailymed-other
TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). This indication is approved under accelerated approval based on overall response rate and durability of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
- generic_name
- brexucabtagene autoleucel
- product_names
- brexucabtagene autoleucel
- ndc
- 71287-219, 71287-219-01, 71287-219-02, 71287-220, 71287-220-01, 71287-220-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en